Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Icecure Medical (ICCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ICCM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.59
1 Year Target Price $2.59
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.65% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.02M USD | Price to earnings Ratio - | 1Y Target Price 2.59 |
Price to earnings Ratio - | 1Y Target Price 2.59 | ||
Volume (30-day avg) 3 | Beta 2.48 | 52 Weeks Range 0.47 - 1.63 | Updated Date 09/17/2025 |
52 Weeks Range 0.47 - 1.63 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -644.76% |
Management Effectiveness
Return on Assets (TTM) -76.4% | Return on Equity (TTM) -230.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 67011750 | Price to Sales(TTM) 25.13 |
Enterprise Value 67011750 | Price to Sales(TTM) 25.13 | ||
Enterprise Value to Revenue 24.04 | Enterprise Value to EBITDA -2.63 | Shares Outstanding 68651696 | Shares Floating 37894170 |
Shares Outstanding 68651696 | Shares Floating 37894170 | ||
Percent Insiders 40.6 | Percent Institutions 0.36 |
Upturn AI SWOT
Icecure Medical
Company Overview
History and Background
IceCure Medical was founded in 2006 and is headquartered in Caesarea, Israel. The company focuses on developing and commercializing minimally invasive cryoablation technology for tumor treatment.
Core Business Areas
- Cryoablation Technology: Development and commercialization of cryoablation systems for treating various benign and malignant tumors.
Leadership and Structure
The leadership team includes Eyal Shamir (CEO). The company operates with a management team overseeing various departments, including R&D, operations, and commercialization.
Top Products and Market Share
Key Offerings
- ProSense System: ProSense is IceCure Medical's flagship cryoablation system used for treating tumors. It uses liquid nitrogen to freeze and destroy tumors. While specific market share data is limited, the cryoablation market is competitive. Competitors include Galil Medical (acquired by Boston Scientific), Medtronic, and EDAP TMS. ProSense revenue is not publicly broken out. Estimated number of users unavailable.
Market Dynamics
Industry Overview
The cryoablation market is growing due to increasing demand for minimally invasive cancer treatments. Key drivers include an aging population and advancements in cryoablation technology.
Positioning
IceCure Medical focuses on providing accessible and minimally invasive cryoablation solutions. They are positioned as a company offering alternatives to traditional surgical procedures.
Total Addressable Market (TAM)
The global cryoablation market is expected to reach billions of dollars. IceCure Medical is positioned to capture a share of this market by expanding its product offerings and geographical reach.
Upturn SWOT Analysis
Strengths
- Minimally invasive technology
- FDA clearance for breast cancer treatment
- Proprietary cryoablation system
Weaknesses
- Limited commercial presence
- High reliance on key products
- Negative Earnings
Opportunities
- Expanding into new geographical markets
- Developing new applications for cryoablation technology
- Strategic partnerships
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- BSX
- MDT
- EDAP
Competitive Landscape
IceCure Medical faces competition from larger, more established medical device companies. Its advantages include proprietary technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is difficult to assess due to its early stage. Future growth is expected.
Future Projections: Future growth projections not available.
Recent Initiatives: Initiatives include pursuing regulatory approvals and expanding clinical trials.
Summary
IceCure Medical is a developing company with a unique cryoablation system. While its minimally invasive ProSense System has promise, it faces challenges including its competitors. Strategic initiatives like expanding clinical trials will be necessary to grow and succeed. Investors should note the high amount of competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Icecure Medical
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-08-26 | CEO & Director Mr. Eyal Shamir | ||
Sector Healthcare | Industry Medical Devices | Full time employees 64 | Website https://www.icecure-medical.com |
Full time employees 64 | Website https://www.icecure-medical.com | ||
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.